(VIANEWS) – SCYNEXIS (SCYX), Corcept Therapeutics Incorporated (CORT), Zynex (ZYXI) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SCYNEXIS (SCYX)
889.4% sales growth and 132.23% return on equity
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Earnings Per Share
As for profitability, SCYNEXIS has a trailing twelve months EPS of $1.49.
PE Ratio
SCYNEXIS has a trailing twelve months price to earnings ratio of 1.33. Meaning, the purchaser of the share is investing $1.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 132.23%.
2. Corcept Therapeutics Incorporated (CORT)
16.1% sales growth and 19.55% return on equity
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Earnings Per Share
As for profitability, Corcept Therapeutics Incorporated has a trailing twelve months EPS of $0.8.
PE Ratio
Corcept Therapeutics Incorporated has a trailing twelve months price to earnings ratio of 29.31. Meaning, the purchaser of the share is investing $29.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.55%.
Yearly Top and Bottom Value
Corcept Therapeutics Incorporated’s stock is valued at $23.45 at 00:22 EST, way below its 52-week high of $34.28 and way higher than its 52-week low of $17.86.
Volume
Today’s last reported volume for Corcept Therapeutics Incorporated is 1417360 which is 46.96% above its average volume of 964426.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 78.6% and 42.9%, respectively.
3. Zynex (ZYXI)
13.2% sales growth and 25.8% return on equity
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Earnings Per Share
As for profitability, Zynex has a trailing twelve months EPS of $0.43.
PE Ratio
Zynex has a trailing twelve months price to earnings ratio of 24.63. Meaning, the purchaser of the share is investing $24.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.8%.
Sales Growth
Zynex’s sales growth is 11.7% for the current quarter and 13.2% for the next.
Volume
Today’s last reported volume for Zynex is 190149 which is 44.19% below its average volume of 340768.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Zynex’s EBITDA is 45.79.
4. Mastercard (MA)
11.9% sales growth and 170.45% return on equity
Mastercard Incorporated, a technology company, provides transaction processing and other payment-related products and services in the United States and internationally. It facilitates the processing of payment transactions, including authorization, clearing, and settlement, as well as delivers other payment-related products and services. The company offers integrated products and value-added services for account holders, merchants, financial institutions, businesses, governments, and other organizations, such as programs that enable issuers to provide consumers with credits to defer payments; payment products and solutions that allow its customers to access funds in deposit and other accounts; prepaid programs services; and commercial credit, debit, and prepaid payment products and solutions. It also provides value-added products and services comprising cyber and intelligence solutions for parties to transact, as well as proprietary insights, drawing on principled use of consumer, and merchant data services. In addition, the company offers analytics, test and learn, consulting, managed services, loyalty, processing, and payment gateway solutions for e-commerce merchants. Further, it provides open banking and digital identity platforms services. The company offers payment solutions and services under the MasterCard, Maestro, and Cirrus. Mastercard Incorporated was founded in 1966 and is headquartered in Purchase, New York.
Earnings Per Share
As for profitability, Mastercard has a trailing twelve months EPS of $11.49.
PE Ratio
Mastercard has a trailing twelve months price to earnings ratio of 38.12. Meaning, the purchaser of the share is investing $38.12 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 170.45%.
Previous days news about Mastercard(MA)
- According to Zacks on Wednesday, 24 January, "A handful of companies from the sector, likeBooz Allen Hamilton Holding Corporation (BAH Quick QuoteBAH – Free Report) , FLEETCOR Technologies, Inc. (FLT Quick QuoteFLT – Free Report) , Rollins, Inc. (ROL Quick QuoteROL – Free Report) and Mastercard Incorporated (MA Quick QuoteMA – Free Report) , are expected to beat estimates in the ongoing reporting cycle."
- According to Zacks on Friday, 26 January, "Analysts’ assessment points toward ‘Gross dollar volume – All Mastercard Credit, Charge and Debit Programs – Worldwide’ reaching $2,368.11 billion. ", "The combined assessment of analysts suggests that ‘Gross dollar volume – All Mastercard Credit, Charge and Debit Programs – Latin America’ will likely reach $197.40 billion. "
5. Booz Allen Hamilton Holding Corporation (BAH)
8.1% sales growth and 25.71% return on equity
Booz Allen Hamilton Holding Corporation provides management and technology consulting, analytics, engineering, digital, mission operations, and cyber solutions to governments, corporations, and not-for-profit organizations in the United States and internationally. The company offers consulting solutions for various domains, business strategies, human capital, and operations. It also provides analytics services, which focuses on delivering transformational solutions in the areas of artificial intelligence, such as machine learning, deep learning; data science, such as data engineering and predictive modeling; automation and decision analytics; and quantum computing. In addition, the company designs, develops, and implements solutions built on contemporary methodologies and modern architectures; delivers engineering services and solutions to define, develop, implement, sustain, and modernize complex physical systems; and provides cyber risk management solutions, such as prevention, detection, and cost effectiveness. Booz Allen Hamilton Holding Corporation was founded in 1914 and is headquartered in McLean, Virginia.
Earnings Per Share
As for profitability, Booz Allen Hamilton Holding Corporation has a trailing twelve months EPS of $2.24.
PE Ratio
Booz Allen Hamilton Holding Corporation has a trailing twelve months price to earnings ratio of 58.03. Meaning, the purchaser of the share is investing $58.03 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.71%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Nov 13, 2023, the estimated forward annual dividend rate is 1.88 and the estimated forward annual dividend yield is 1.45%.
Yearly Top and Bottom Value
Booz Allen Hamilton Holding Corporation’s stock is valued at $129.98 at 00:22 EST, under its 52-week high of $131.28 and way higher than its 52-week low of $87.99.
Previous days news about Booz Allen Hamilton Holding Corporation(BAH)
- According to Zacks on Wednesday, 24 January, "Booz Allen Hamilton Holding Corporation price-eps-surprise | Booz Allen Hamilton Holding Corporation Quote"
- According to Zacks on Wednesday, 24 January, "Booz Allen Hamilton Holding Corporation price-eps-surprise | Booz Allen Hamilton Holding Corporation Quote"
6. ExlService Holdings (EXLS)
7.4% sales growth and 22.57% return on equity
ExlService Holdings, Inc. operates as a data analytics, and digital operations and solutions company in the United States and internationally. It operates through Insurance, Healthcare, Analytics, and Emerging Business segments. The company provides digital operations and solutions and analytics-driven services across the insurance industry in areas, such as claims processing, premium and benefit administration, agency management, account reconciliation, policy research, underwriting support, new business acquisition, policy servicing, premium audit, surveys, billing and collection, commercial and residential survey, and customer service using digital technology, artificial intelligence, machine learning, and advanced automation; digital customer acquisition services using a software-as-a-service delivery model through LifePRO and LISS platforms; subrogation services; and Subrosource software platform, an end-to-end subrogation platform. It also offers CareRadius, an integrated care management offering; and health care services related to care management, utilization management, disease management, payment integrity, revenue optimization and customer engagement to healthcare payers, providers, pharmacy benefit managers, and life sciences organizations. Further, it offers predictive and prescriptive analytics in the areas of customer acquisition and lifecycle management, risk underwriting and pricing, operational effectiveness, credit and operational risk monitoring and governance, payment integrity and care management, and data management. The company was founded in 1999 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, ExlService Holdings has a trailing twelve months EPS of $1.05.
PE Ratio
ExlService Holdings has a trailing twelve months price to earnings ratio of 29.39. Meaning, the purchaser of the share is investing $29.39 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.57%.
Volume
Today’s last reported volume for ExlService Holdings is 545308 which is 47.88% below its average volume of 1046390.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 9.7% and 8.6%, respectively.
7. Navigator Holdings Ltd. Ordinary Shares (NVGS)
6.5% sales growth and 6.55% return on equity
Navigator Holdings Ltd. owns and operates a fleet of liquefied gas carriers worldwide. It provides international and regional seaborne transportation services of petrochemical gases, liquefied petroleum gases, and ammonia for energy companies, industrial users, and commodity traders. The company also offers ship shore infrastructure and consultancy services. It operates a fleet of 56 semi- or fully-refrigerated liquefied gas carriers. The company was formerly known as Isle of Man public limited company and changed its name to Navigator Holdings Ltd. in 2006. Navigator Holdings Ltd. was incorporated in 1997 and is headquartered in London, the United Kingdom.
Earnings Per Share
As for profitability, Navigator Holdings Ltd. Ordinary Shares has a trailing twelve months EPS of $0.99.
PE Ratio
Navigator Holdings Ltd. Ordinary Shares has a trailing twelve months price to earnings ratio of 16.29. Meaning, the purchaser of the share is investing $16.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.55%.
Volume
Today’s last reported volume for Navigator Holdings Ltd. Ordinary Shares is 103971 which is 36.61% below its average volume of 164032.
Sales Growth
Navigator Holdings Ltd. Ordinary Shares’s sales growth is 1.4% for the present quarter and 6.5% for the next.
Moving Average
Navigator Holdings Ltd. Ordinary Shares’s worth is higher than its 50-day moving average of $14.91 and way higher than its 200-day moving average of $13.99.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 135.7% and 28%, respectively.
8. Universal Health Services (UHS)
5.8% sales growth and 11.15% return on equity
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. The company operates through Acute Care Hospital Services and Behavioral Health Care Services segments. Its hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric services, pharmacy services, and/or behavioral health services. The company also provides commercial health insurance services; and various management services, which include central purchasing, information, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Earnings Per Share
As for profitability, Universal Health Services has a trailing twelve months EPS of $9.52.
PE Ratio
Universal Health Services has a trailing twelve months price to earnings ratio of 16.21. Meaning, the purchaser of the share is investing $16.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.15%.
Moving Average
Universal Health Services’s value is way above its 50-day moving average of $139.58 and way above its 200-day moving average of $136.82.
